| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Outline of Final Research Achievements |
Orexin system is involved in the regulation of both emotion and central glucose metabolism. Intracerebroventricular injection of orexin at active wake phase improved glucose metabolism via amelioration of ER stress responses and hepatic glucose production in diabetic db/db mice. In addition, orexin prevented chronic stress-induced glucose intolerance and insulin resistance in mice. Moreover, chronic nicotine treatment at active wake phase that enhances orexin expression improved glucose intolerance via inhibition of hepatic glucose production in db/db mice. Thus, orexin system plays a crucial role to centrally prevent glucose intolerance and hepatic insulin resistance caused by obesity and depression. The timed activation of orexin system is a new therapeutic target for diabetes with dysregulation of sleep/wake rhythm and/or depressive disorders.
|
